Clinical Effect Analysis of Selegiline Combined with Amantadine Salt in the Treatment of Parkinson's Disease Patients
Objective To explore the clinical effect and safety of Selegiline combined with amantadine in the treat-ment of patients with Parkinson's disease.Methods A total of 94 patients with Parkinson's disease treated in Shuyang Renren Hospital of Suqian City from January 2021 to January 2023 were selected as the study objects,and were di-vided into control group and observation group by random number table method,with 47 patients in each group.The control group was treated with Selegiline,and the observation group was treated with amantadine hydrochloride on the basis of the control group,and the treatment lasted for 6 months.The effective rate of clinical treatment,the changes of dopamine,5-hydroxytryptamine and brain-derived neurotrophic factor concentrations and the incidence of adverse reactions were compared between the two groups.Results The effective rate of the observation group was 82.98%,which was higher than that of the control group(63.83%),the difference was statistically significant(P<0.05).After treatment,the serum concentrations of dopamine,5-hydroxytryptamine and brain-derived neurotrophic factor in obser-vation group were higher than those in control group,and the differences were statistically significant(all P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Selegiline combined with amantadine salt can significantly improve the clinical symptoms and improve the quality of life of patients,and has certain safety.
Parkinson's diseaseAmantadine saltSelegilineNeurotransmitterQuality of life
NETL
NSTL
万方数据
维普
